celecoxib has been researched along with Acute Liver Injury, Drug-Induced in 33 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report in this study that a clinically available COX-2 inhibitor, celecoxib, exacerbates porcine serum (PS)-induced hepatic fibrosis and induces hepatocellular necrosis in an experimental liver fibrosis model." | 7.75 | Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum. ( Li, X; Liu, H; Wei, W, 2009) |
| " We report in this study that a clinically available COX-2 inhibitor, celecoxib, exacerbates porcine serum (PS)-induced hepatic fibrosis and induces hepatocellular necrosis in an experimental liver fibrosis model." | 3.75 | Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum. ( Li, X; Liu, H; Wei, W, 2009) |
| "This is the fourth report in the English-language literature describing cholestatic hepatitis temporally related to celecoxib use, the second supported by histologic findings typical of drug-induced cholestasis, and the first in a patient who denied use of alcoholic beverages and was taking no other drugs or herbal products at the time of the reaction." | 3.71 | Acute cholestatic hepatitis associated with celecoxib. ( Civello, IM; Gasbarrini, G; Giorgi, A; Grieco, A; Miele, L, 2002) |
| " Four additional DILI cases were identified after LY3031207 dosing had been stopped." | 2.87 | Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor. ( Campanale, K; Hall, DG; Henck, J; Hu, L; Jin, Y; Kam, J; Landschulz, W; McNearney, TA; Nakano, M; Phipps, K; Regev, A; Smith, C; Uetrecht, J; Yang, XY, 2018) |
| "Celecoxib is a widely prescribed nonsteroidal anti-inflammatory drug, and has been associated with rare instances of idiosyncratic drug-induced liver injury (DILI)." | 2.58 | Celecoxib-induced Liver Injury: Analysis of Published Case Reports and Cases Reported to the Food and Drug Administration. ( Chalasani, N; Fontana, RJ; Ghabril, M; Mukthinuthalapati, PK; Vuppalanchi, R, 2018) |
| "Glycogen was decreased by CCl(4), while celecoxib partially prevented and reversed this effect." | 1.36 | Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat. ( Castro-Sánchez, L; Chávez, E; Moreno, MG; Muriel, P; Salazar, EP; Segovia, J; Shibayama, M; Tsutsumi, V; Vergara, P, 2010) |
| "Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) which acts via specific inhibition of cyclooxygenase-2 (synthesis of prostaglandins mediating pathological inflammation) but which preserves the homeostatic action of cyclooxygenase-1." | 1.32 | [Hypersensitivity to celecoxib]. ( Chiffoleau, A; Fradet, G; Huguenin, H; Robin-Le Nechet, A, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (54.55) | 29.6817 |
| 2010's | 14 (42.42) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Fourches, D | 1 |
| Barnes, JC | 1 |
| Day, NC | 1 |
| Bradley, P | 1 |
| Reed, JZ | 1 |
| Tropsha, A | 1 |
| Ekins, S | 1 |
| Williams, AJ | 1 |
| Xu, JJ | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 2 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Chen, M | 1 |
| Suzuki, A | 1 |
| Thakkar, S | 1 |
| Yu, K | 1 |
| Hu, C | 1 |
| Ullah, U | 1 |
| Badshah, H | 1 |
| Malik, Z | 1 |
| Uddin, Z | 1 |
| Alam, M | 1 |
| Sarwar, S | 1 |
| Aman, A | 1 |
| Khan, AU | 1 |
| Shah, FA | 1 |
| Mukthinuthalapati, PK | 1 |
| Fontana, RJ | 1 |
| Vuppalanchi, R | 1 |
| Chalasani, N | 1 |
| Ghabril, M | 1 |
| Drmic, D | 1 |
| Kolenc, D | 1 |
| Ilic, S | 1 |
| Bauk, L | 1 |
| Sever, M | 1 |
| Zenko Sever, A | 1 |
| Luetic, K | 1 |
| Suran, J | 1 |
| Seiwerth, S | 1 |
| Sikiric, P | 1 |
| Jin, Y | 1 |
| Regev, A | 1 |
| Kam, J | 1 |
| Phipps, K | 1 |
| Smith, C | 1 |
| Henck, J | 1 |
| Campanale, K | 1 |
| Hu, L | 1 |
| Hall, DG | 1 |
| Yang, XY | 1 |
| Nakano, M | 1 |
| McNearney, TA | 1 |
| Uetrecht, J | 1 |
| Landschulz, W | 1 |
| Larrey, E | 1 |
| Patouraux, S | 1 |
| Spreux, A | 1 |
| Canivet, CM | 1 |
| Piche, T | 1 |
| Tran, A | 1 |
| Anty, R | 1 |
| El-Kashef, DH | 1 |
| El-Sheakh, AR | 1 |
| Liu, H | 1 |
| Wei, W | 1 |
| Li, X | 1 |
| Arlorio, M | 1 |
| Bottini, C | 1 |
| Travaglia, F | 1 |
| Locatelli, M | 1 |
| Bordiga, M | 1 |
| Coïsson, JD | 1 |
| Martelli, A | 1 |
| Tessitore, L | 1 |
| Washino, Y | 1 |
| Koga, E | 1 |
| Kitamura, Y | 1 |
| Kamikawa, C | 1 |
| Kobayashi, K | 1 |
| Nakagawa, T | 1 |
| Nakazaki, C | 1 |
| Ichi, I | 1 |
| Kojo, S | 1 |
| Chávez, E | 1 |
| Segovia, J | 1 |
| Shibayama, M | 1 |
| Tsutsumi, V | 1 |
| Vergara, P | 1 |
| Castro-Sánchez, L | 1 |
| Salazar, EP | 1 |
| Moreno, MG | 1 |
| Muriel, P | 1 |
| Lee, CH | 1 |
| Wang, JD | 1 |
| Chen, PC | 1 |
| Famularo, G | 1 |
| Gasbarrone, L | 1 |
| Minisola, G | 1 |
| Mohammed, F | 1 |
| Smith, AD | 1 |
| Grieco, A | 1 |
| Miele, L | 1 |
| Giorgi, A | 1 |
| Civello, IM | 1 |
| Gasbarrini, G | 1 |
| Waldum, HL | 1 |
| Fradet, G | 1 |
| Robin-Le Nechet, A | 1 |
| Huguenin, H | 1 |
| Chiffoleau, A | 1 |
| Perna, AG | 1 |
| Woodruff, CA | 1 |
| Markus, RF | 1 |
| Hsu, S | 1 |
| Sanchez-Matienzo, D | 1 |
| Arana, A | 1 |
| Castellsague, J | 1 |
| Perez-Gutthann, S | 1 |
| Dastis, SN | 1 |
| Rahier, J | 1 |
| Lerut, J | 1 |
| Geubel, AP | 1 |
| Tabibian, JH | 1 |
| Tabibian, N | 1 |
| Kaufman, DM | 1 |
| Fleischmann, R | 1 |
| Tannenbaum, H | 1 |
| Patel, NP | 1 |
| Notter, M | 1 |
| Sallstig, P | 1 |
| Reginster, JY | 1 |
| Carrillo-Jimenez, R | 1 |
| Nurnberger, M | 1 |
| Galan, MV | 1 |
| Gordon, SC | 1 |
| Silverman, AL | 1 |
| O'Beirne, JP | 1 |
| Cairns, SR | 1 |
| Nachimuthu, S | 1 |
| Volfinzon, L | 1 |
| Gopal, L | 1 |
| Reilly, TP | 1 |
| Brady, JN | 1 |
| Marchick, MR | 1 |
| Bourdi, M | 1 |
| George, JW | 1 |
| Radonovich, MF | 1 |
| Pise-Masison, CA | 1 |
| Pohl, LR | 1 |
| Arellano, FM | 1 |
| Zhao, SZ | 1 |
| Reynolds, MW | 1 |
| Alegria, P | 1 |
| Lebre, L | 1 |
| Chagas, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 52-week, International, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Clinical Trial to Compare Retention on Treatment, Safety, Tolerability and Efficacy of Lumiracoxib 100 mg od, Lumiracoxib 100 mg Bid and Celecoxib 200 mg od in [NCT00145301] | Phase 3 | 3,036 participants | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for celecoxib and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Pr | 2016 |
Celecoxib-induced Liver Injury: Analysis of Published Case Reports and Cases Reported to the Food and Drug Administration.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemical and Dru | 2018 |
Toxic epidermal necrolysis as a complication of treatment with celecoxib.
Topics: Aged; Aged, 80 and over; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase Inhibitor | 2003 |
Acute hepatocellular and cholestatic injury in a patient taking celecoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemical and Drug Induced Liver Injury; Ch | 2001 |
2 trials available for celecoxib and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor.
Topics: Administration, Oral; Adult; Area Under Curve; Celecoxib; Chemical and Drug Induced Liver Injury; Cy | 2018 |
Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis.
Topics: Aged; Arthralgia; Canada; Cardiovascular Diseases; Celecoxib; Chemical and Drug Induced Liver Injury | 2008 |
27 other studies available for celecoxib and Acute Liver Injury, Drug-Induced
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLI | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Hepatoprotective effects of melatonin and celecoxib against ethanol-induced hepatotoxicity in rats.
Topics: Animals; Biomarkers; Celecoxib; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; E | 2020 |
Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by BPC 157 or L-arginine, aggravation by L-NAME.
Topics: Animals; Anti-Ulcer Agents; Antidotes; Arginine; Brain; Celecoxib; Chemical and Drug Induced Liver I | 2017 |
Fatal cholestatic hepatitis after a single dose of celecoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemical and Drug Induced Liver Injury; Ch | 2019 |
Hepatoprotective effect of celecoxib against tamoxifen-induced liver injury via inhibiting ASK-1/JNK pathway in female rats.
Topics: Animals; Antineoplastic Agents, Hormonal; Antioxidants; Celecoxib; Chemical and Drug Induced Liver I | 2019 |
Celecoxib exacerbates hepatic fibrosis and induces hepatocellular necrosis in rats treated with porcine serum.
Topics: Animals; Body Weight; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors | 2009 |
Protective activity of Theobroma cacao L. phenolic extract on AML12 and MLP29 liver cells by preventing apoptosis and inducing autophagy.
Topics: Animals; Apoptosis; Cacao; Celecoxib; Cell Line; Cell Survival; Chemical and Drug Induced Liver Inju | 2009 |
Effect of celecoxib, a selective cyclooxygenase-2 inhibitor on carbon tetrachloride intoxication in rats.
Topics: Alanine Transaminase; Animals; Antioxidants; Ascorbic Acid; Aspartate Aminotransferases; Carbon Tetr | 2010 |
Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat.
Topics: Alanine Transaminase; Animals; Anti-Inflammatory Agents; Antioxidants; Aspartate Aminotransferases; | 2010 |
Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; | 2010 |
Probable celecoxib-induced hepatorenal syndrome.
Topics: Aged; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2 Inhibitors; Female; Follow | 2012 |
Cholestatic hepatitis in association with celecoxib. Classification of drug associated liver dysfunction is questionable.
Topics: Celecoxib; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Cyclooxygenase Inhibit | 2002 |
Acute cholestatic hepatitis associated with celecoxib.
Topics: Acute Disease; Adult; Alanine Transaminase; Anti-Inflammatory Agents, Non-Steroidal; Aspartate Amino | 2002 |
Comment: acute cholestatic hepatitis associated with celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biliary Tract; Celecoxib; Chemical and Drug Induced Liver I | 2003 |
[Hypersensitivity to celecoxib].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemical and Drug Induced Liver Injury; Dr | 2003 |
Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Benzophenones; Bromobenzenes; Celecoxib; Chemical and Drug | 2006 |
Liver transplantation for nonsteroidal anti-inflammatory drug-induced liver failure: nimesulide as the first implicated compound.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemical and Drug Induced Liver Injury; F | 2007 |
Late-onset celecoxib-induced combined hepato-nephrotoxicity.
Topics: Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase Inhibitors; Humans; Kidney Disease | 2008 |
Celecoxib-induced acute pancreatitis and hepatitis: a case report.
Topics: Acute Disease; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemical | 2000 |
Celecoxib-induced cholestatic hepatitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemical and Drug Induced Liver Injury; Cholesta | 2001 |
Drug Points: Cholestatic hepatitis in association with celecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemical and Drug Induced Liver Injury; Cholesta | 2001 |
A protective role for cyclooxygenase-2 in drug-induced liver injury in mice.
Topics: Acetaminophen; Animals; Celecoxib; Chemical and Drug Induced Liver Injury; Cyclooxygenase 2; Cycloox | 2001 |
Case of cholestatic hepatitis with celecoxib did not fulfil international criteria.
Topics: Celecoxib; Chemical and Drug Induced Liver Injury; Cholestasis, Intrahepatic; Cyclooxygenase Inhibit | 2002 |
Celecoxib-induced cholestatic hepatotoxicity in a patient with cirrhosis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemical and Drug Induced Liver Injury; Cholesta | 2002 |